GLP-1 Drugs Reshaping Restaurant Industry: 12% of US Adults on Therapy, 8% Spending Cut at Fast Food
The rapid spread of GLP-1 weight-loss drugs is driving measurable changes in American restaurant spending and industry strategy.
Consumer Behavior Data
- Gallup polling: more than 12% of Americans reported taking GLP-1 drugs for weight loss in fall 2025, up from 6% in early 2024 — the figure has doubled
- J.P. Morgan estimate: over 30 million Americans on GLP-1s by 2030, especially as oral formulations gain traction
- Cornell University study of 150,000 households: families with at least one GLP-1 user cut fast-food, café, and quick-service spending by 8% within six months of starting treatment
Restaurant Industry Response
- McDonald's: highlighting protein content more prominently (GLP-1 users focused on muscle preservation)
- KFC: investing in smaller portions and snack-sized options
- Panera Bread: ~17% of customers use GLP-1s (above national average); introduced half-sandwich-and-salad combos and smaller-portioned options
- Olive Garden: launched a lighter-portions menu nationally
- Chipotle and fast-casual chains with customizable, perceived-healthier options appear to be relative beneficiaries
Investment Implications
- High-exposure names at risk: chains reliant on large portions, fried food, and overconsumption
- Fast-casual chains with protein-forward, customizable menus may gain share
- Food industry broadly sees this as a durable shift, not a passing trend, with some experts cautioning that patients who discontinue treatment may partially revert
- The trend adds to broader consumer headwinds for restaurant stocks already facing inflation pressure (restaurant menu prices climbed 0.7% in April 2026)